BARCELONA, Spain—The gout drug allopurinol on top of usual care does not improve cardiovascular outcomes in patients over age 60 who do not have gout, the ALL-HEART trial confirms. The long-running ...

Allopurinol, a frequently used gout medication, does not appear to drive up the risk for dying among gout patients who also struggle with chronic kidney disease, new research shows. The finding is ...

October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ALLOPURINOL ALPHAPHARM contains the active ingredient allopurinol.

Allopurinol treatment is not associated with increased mortality in patients with gout and chronic kidney disease even at 5 years after starting treatment, a study has found. Around 1 in 5 patients ...

Please provide your email address to receive an email when new articles are posted on . Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy ...

Among patients with gout, allopurinol use is associated with a lower risk for urolithiasis compared with benzbromarone. Among patients with gout, allopurinol use is associated with a lower risk for ...

Benzbromarone, a urate-lowering drug, appeared effective among patients with high serum uric acid levels who had no evidence of gout flares. Benzbromarone may reduce the risk of developing chronic ...

Please provide your email address to receive an email when new articles are posted on . “Therefore, it is very important for patients and clinicians alike to be aware of the cardiovascular safety of ...